Skip to main content
. Author manuscript; available in PMC: 2009 Nov 1.
Published in final edited form as: Clin Cancer Res. 2008 Nov 1;14(21):6867–6876. doi: 10.1158/1078-0432.CCR-08-0093

Figure 2. Persistent AKT activation in cisplatin-resistant PC9 cells.

Figure 2

Cell lysates from PC9 and PC9 (CR) treated with increasing concentrations of erlotinib for 4 hours were analyzed by SDS-PAGE followed by immunoblotting using antibodies directed against the indicated signal transduction proteins.